Skip to content

Efficacy of Unani drug in comparison to conventional drug in the treatment of Dyslipidaemia (abnormal lipid level in blood)

A Randomized, Parallel Group, Open Label, Active Controlled Clinical Study to Evaluate the Safety and Efficacy of Unani Formulation in the management of Khalal shahmiyyat al-dam (Dyslipidaemia) - NIL

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/03/082583
Enrollment
45
Registered
2025-03-18
Start date
Unknown
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E789- Disorder of lipoprotein metabolism, unspecified

Interventions

Intervention1: Group A :Test group(Unani drug): Unani formulation:Method of preparation-the test drug will be prepared in single batch as per the guidelines and method of preparation described in GHIN

Sponsors

National Research Institute Of Unani Medicine For Skin Disorders
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: participants of any sex aged 20-60 years.participants having any one or more of the following lipid abnormality in blood:Total Cholesterol equal to or more than 200mg/dl.Serum LDL Cholesterol equal to or more than 130 mg/dl.Serum HDL Cholesterol less than 40mg/dl .Serum Triglyceride 150-400mg/dl.Body Mass Index 23-40 kg/m2 .

Exclusion criteria

Exclusion criteria: Patients aged less than 20 years or more than 60 years. Serum Triglyceride less than 150 mg/dl or more than 400 mg/dl. Body Mass Index (BMI) less than 23 or more than 40 kg/m2. Uncontrolled hypertension,diabetes mellitus,or other systemic diseases. History of angina or myocardial infarction Pregnant or Lactating Women. Significant Pulmonary,Cardiovascular,Hepatic,or renal Dysfunction. Immunocompromised states (HIV/ AIDS)/ Malignancies. Unwillingness to adhere to the treatment schedule.

Design outcomes

Primary

MeasureTime frame
Biochemical assessment of the change in Lipid and Lipoprotein level.Timepoint: At baseline and 8th week.

Secondary

MeasureTime frame
Reduction in BMI , Waist Circumference,Hip and Waist Ratio and Weight.Timepoint: At baseline and 8th week.

Countries

India

Contacts

Public ContactDr Arzeena Jabeen

National Research Institute Of Unani Medicine For Skin Disorders

aarzu763@gmail.com9032519286

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026